Erick Saldanha: The role of ctDNA clearance as a biomarker of neoadjuvant immune checkpoint blockade in solid tumours
Erick Saldanha, Medical Oncologist and Postdoctoral Clinical Fellow at Princess Margaret Cancer Centre, shared a post on X:
“Thrilled to share our paper, just out in the Annals of Oncology, ESMO.
We assessed the role of ctDNA clearance as a biomarker of neoadjuvant immune checkpoint blockade response for patients with solid tumours. Proud to be part of this effort alongside a brilliant group of colleagues and my dear friend Valenza Carmine.
Luís Felipe Leite, Medical Student at Universidade Federal Fluminense, shared Erick Saldanha‘s post on X, adding:
“Absence of ctDNA clearance may identify patients unlikely to achieve pCR after neoadjuvant ICIs.
However, limited specificity means current evidence does not support its use to guide treatment de-escalation. Impressive analysis by Dr. Saldanha in the Annals of Oncology.”
Authors: Valenza Carmine, Erick Saldanha et al.
Learn more about immunotherapy on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023